Uh-oh! CRISPR gene-editing stocks may be worthless – USA TODAY
USA TODAY |
Uh-oh! CRISPR gene-editing stocks may be worthless
USA TODAY The big-ticket item is that this journal article reported that most humans probably have pre-existing immune defenses against the "cutting element" in CRISPR known as Cas9. If true, the CRISPR-Cas9 gene-editing system may be toxic to the vast majority … |
